Unfortunately, we have not been able to conduct a study looking at our markers for reoccurrence in breast cancer, so without that data is difficult to say for sure. While we did have triple negative cases in our breast cancer clinical data set we used for validating the test in our CLIA lab that was all accurately classified, the overall number was quite small, and they were newly diagnosed cases not under treatment. It’s very likely that long-term treatment for metastatic breast cancer could impact the expression of our markers.